Clinical Trials India | Diabetes CRO India | Clinical trial management India | Clinical research trials India | Oncology CRO India India Clinical Research

Johnson & Johnson to Buy $1 Billion Elan Corporation PLC Stake, Work on Alzheimer's

Bloomberg -- Johnson & Johnson agreed to pay $1 billion for a stake in Elan Corp. and will develop the Irish drugmakers medicines against Alzheimers disease.

Over 250 New Jobs at Eisai Company, Ltd.'s New HQ

<script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...

NeoGenomics Laboratories Expansion to Create 75 New Jobs in Lee County

How Does the Faltering Economy Affect Jobs in Pharmaceutical Services?

What to Discuss During Interviews for Jobs in the Biotechnology Field

Pfizer Inc.'s Sutent Fails in Colon Cancer, Trial Halted

Maxygen, Inc. Plans Staff Cuts After Forming R&D Joint Venture With Astellas Pharma Inc.

BizJournals -- Maxygen Inc. and Japanese drug maker Astellas Pharma Inc. will start an R&D joint venture focused on protein drugs but largely spelling the beginning of the end of the Redwood City company as it is known today.

CombinatoRx, Incorporated to Merge with Privately Held Neuromed Pharmaceuticals

Maxygen, Inc., Astellas Pharma Inc. Seal Research Pact, CEO will Exit

Roche Drops Out Of PhRMA, Joins Biotechnology Industry Organization (BIO)

Biogen Idec, Inc. (Massachusetts) Gains Rights to Acorda Therapeutics's MS Drug; to Get $110 Million Up Front

Interferon Alpha Can Delay Full Onset Of Type I Diabetes, University of Texas Medical School Study

EurekAlert! -- HOUSTON (July 1, 2009) A low dose of oral interferon alpha shows promise in preserving beta cell function for patients with newly diagnosed type 1 diabetes, or juvenile diabetes, according to researchers at The University of Texas Medical School at Houston.

Creation of New Jobs Planned for

Ketamine Safe for Endrotracheal Intubation, Study

TB Vaccine Could Kill Babies With HIV, World Health Organization Reports

Acid-Reducing Medicines May Lead To Dependency, University of Copenhagen Study

Medidata Solutions, Inc. Prices Initial Public Offering

NEW YORK--(BUSINESS WIRE)--Medidata Solutions, a leading global provider of hosted clinical development solutions, today announced the pricing of its initial public offering of 6,300,000 shares of common stock at $14.00 per share. In addition, selling stockholders have granted the underwriters a 30-day option to purchase up to 945,000 shares of common stock at the initial public offering price to cover...

Radiation Not Needed In Common Childhood Cancer, St. Jude Children's Research Hospital Study

Medtronic, Inc. And Stryker Corporation Bone-Growth Proteins Show Risk in New Study At Brigham and Women's Hospital

UCB Group and Biogen Idec, Inc. (Massachusetts) Discontinue Phase II Clinical Trial of CDP323

Repros Therapeutics Inc. to Stop Using 50 mg Dose in Fibroids Study

Study Dismisses Protein's Role in Heart Disease, Imperial College London Study

Children Can Inhale Growth Hormone, Study

News-Medical -- A multi-center clinical trial led by a Riley Hospital for Children endocrinologist has found that inhaled growth hormone (GH) is well tolerated by children with GH deficiency and that this easy-to-use method can, over a one-week period, safely deliver GH to the blood stream. In addition to having implications for those who need GH, this first pediatric study of administering it through...

Tumor-Suppressor Recruits Help To Overcome A Barrier And Fix Cancer-causing Defects, University of Texas MD Anderson Cancer Center Study

Novartis Corporation Sees FDA Decision on Menveo Early 2010 US After Regulator Seeks More Data on Meningitis Vaccine

FDA Approves AMAG Pharmaceuticals, Inc.'s Feraheme(TM) to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients

Eisai Corporation of North America and Pfizer Inc. Decide not to Appeal NICE Decision and Call for an Expedited Review of Guidance for Alzheimer's Disease

NeoStem, Inc. Raises Additional Funds from Principals of and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million

Novel Epigenetic Markers Of Melanoma May Herald New Treatments For Patients, Yale University Study

U.S. FDA Casts Doubt on Lantus Cancer Link

Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company

Spectrum Pharmaceuticals, Inc. to Raise $21 Million from Institutional Investors at $7.1525 Per Share

Charles River Laboratories (Massachusetts) Announces RMS Succession Plan and Organizational Enhancements

Morphotek Inc. Announces a Research Collaboration Agreement with Synageva BioPharma to Develop Potential Treatments for Cancer and Infectious Disease

Europe Approves AstraZeneca PLC Lung Cancer Drug

Georgetown University Medical Center Study May Help Explain "Awakenings" That Occur With Popular Sleep-Aid Ambien

Sanofi-Aventis (France) Remodels R&D, Eight Sites Close, No Forced Layoffs

AMAG Pharmaceuticals, Inc. Expects FDA Action on Anemia Drug Within Days

Roche Holding AG Stops Selling Acne Drug Accutane

Facebook Taps Ex-Genentech, Inc. CFO for Finance Chief

Second Gene Linked To Familial Testicular Cancer, National Institutes of Health (NIH) Study

NIH -- Specific variations or mutations in a particular can gene raise a man's risk of familial, or inherited, testicular germ-cell cancer, the most common form of this disease, according to new research by scientists at the National Institutes of Health. This is only the second gene to be identified that affects the risk of familial testicular cancer, and the first gene in a key biochemical pathway...

Wyeth, Catalyst Biosciences, Inc. Sign Deal Worth Potentially $500 Million

Takeda Pharmaceutical Co. Ltd. Fails to Get U.S. Approval for Diabetes Drug

Drug-Resistant Flu Strain Turns Up in Denmark but Doesn???t Last Long

RNA Snippet Suppresses Spread Of Aggressive Breast Cancer, Whitehead Institute Study

Whitehead Institute -- A low cellular level of a tiny fragment of RNA appears to increase the spread of breast cancer in mouse models of the disease, according to researchers at Whitehead Institute for Biomedical Research.

Early Heart Attack Therapy With Bone Marrow Extract Improves Cardiac Function, University of California, San Francisco (UCSF) Study

UCSF -- A UCSF study for the treatment of heart failure after heart attack found that the extract derived from bone marrow cells is as effective as therapy using bone marrow stem cells for improving cardiac function, decreasing the formation of scar tissue and improving cardiac pumping capacity after heart attack.

Diabetics Urged To Stay On Popular Sanofi-Aventis K.K.'s Insulin Lantus

BioSante Pharmaceuticals, Inc. to Buy Cell Genesys, Inc. for $38 Million

Teva Pharmaceutical Industries Limited, Optimata Ltd. Partner to Make Cancer Drugs Work

ULURU Inc. Restructured Operations to Conserve Cash to Further the Company's Business

Women With Cystic Fibrosis Can Have Safe And Successful Fertility Treatment, Study

Hyperion Therapeutics Raises $60 Million Series C

Pfizer Inc. Offers EU Remedies Over Planned Wyeth Buy

Collegium Pharmaceutical, Inc. Announces the Sale of AllerNaze(TM) to Lupin Ltd.

GE Healthcare, Geron Corporation to Develop Stem Cell Products

Sanofi-Aventis (France) Drug May Increase Cancer Risk, Studies Find

Novartis Corporation in Talks to Buy Much of Elan Corporation PLC

TapImmune Inc. Announces Corporate Restructuring

BioPharm Executive: Sprinting to the Finish

Jury Returns $1.67 Billion Drug Verdict Against Abbott Laboratories

PPD, Inc. Confirms Takeda Pharmaceutical Co. Ltd. Receives FDA Complete Response for Alogliptin; to Conduct More Trials

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. today announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for alogliptin.</p><p>PPD is partnering with...

Drug Companies Defend Acetaminophen as FDA Considers Restrictions

Biogen Idec, Inc. (Massachusetts) Reports 10th Case of PML Brain Infection in Patient Taking Tysabri

Vical Incorporated's H1N1 Flu Vaccine Shows Promise

Closed Pore Could Trap Malaria, The Burnet Institute and The Walter and Eliza Hall Institute of Medical Research and Deakin University Report

Scientists Kill Cancer Cells With "Trojan Horse", EnGeneIC Pty Ltd Study

Insulin Analogue Glargine Possibly Increases Cancer Risk,

EurekAlert -- The risk of cancer possibly increases if patients with diabetes use the long-acting insulin analogue glargine instead of human insulin. The Institute for Quality and Efficiency in Health Care (IQWiG), in collaboration with the "Wissenschaftliches Institut der AOK" (WIdO), the research institute of the German Local Health Care Fund, analysed the data of almost 130,000 patients with diabetes...

New Techniques Make More Ovary Transplants Possible, May Help Women Fight Biological Clock, And Studies

Synthetic Biology: Gene Therapy Gets Under The Skin, ETH Zurich Study

A Potent And Selective Anti-Tumor Agent On Human Gastric Cancer, China Medical University Study

Advanced Nerve Cell System Could Help Cure Diabetic Neuropathy, Related Diseases, University of Central Florida Study

Statins Can Protect Against Alzheimer???s Disease, According To New Study At University of Groningen

Gyros AB Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals

Celera Corporation Grants License to Bayer Schering Pharma for Cancer-Related Targets

Lundbeck Inc. (formerly Ovation Pharmaceuticals) Shares Drop as Drug Hits FDA Snag

Paladin Labs Inc. to Buy Some Products from Wyeth

deCODE genetics, Inc. Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis

EU Lifts Restrictions on UCB Group's Neupro

Celesio AG Buys Majority Stake in Brazil's Panpharma

New Drug Promising Against Rheumatoid Arthritis, New Study in Says

News-Medical -- Golimumab, a new tumour necrosis factor-a (TNF-a) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-a inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-a inhibitors, finds an Article published Online first and in this week's edition of The Lancet.

Teva Pharmaceutical Industries Limited and Antares Pharma, Inc. Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin(R)

Adeona Pharmaceuticals Announces Appointment of as Chief Executive Officer and President

University of Texas MD Anderson Cancer Center Researchers Pinpoint A New Enemy For Tumor-Suppressor p53

EurekAlert -- Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells.

New Treatment for Rheumatoid Arthritis Looks Promising, Study

Histamine Affects Alcohol-related Behavior, Study

Mylan Inc. Announces Strategic Collaboration with BioCon Limited to Enter the Global Generic Biologics Market

Researchers Identify A Novel Mechanism That Could Be Targeted To Prevent Cancer Spread, National Cancer Institute Study

Asia's Party Drug Ketamine Carries Incontinence Risk

Reuters - Revelers across Asia who snort the animal tranquilizer ketamine for a hallucinogenic high may face incontinence and other health problems as new dangers of this cheap party drug start showing up in long-term studies.

Promising Biomarker And Candidate Tumor Suppressor Gene Identified For Colorectal Cancer, Maastricht University Medical Center Study

Quotient BioResearch Creates 40 Science Jobs at New ??15 Million Plant

Sanofi Pasteur To Fill US Vaccine Supply Gap Caused By Merck & Co., Inc.

Cancer Researchers Link DICER1 Gene Mutation To Rare Childhood Cancer, Children's National Medical Center Study

FDA Stops Shipments of 33 Generic Drugs from Caraco Pharmaceutical Laboratories, Ltd. Plants

Four Post-Exposure Rabies Jabs Sufficient, Announces

Enzyme Fights Mutated Protein In Inherited Parkinson's Disease, UT Southwestern Medical Center Study

White House: 7 Years Enough To Shield Biotech Drugs

New York State Allows Payment for Egg Donations for Research

Effective Pain Treatment For Cancer Patients?, University of Heidelberg Study

University of Heidelberg -- Cancer patients often suffer from severe pain that cannot be effectively treated with conventional medication. Researchers at the Pharmacology Institute of the University of Heidelberg have found the possible reasons for this tumors release two signal substances that make nerve cells especially sensitive and enhance tumor growth. In animal tests, when the researchers blocked...

Tryptophan Deficiency May Underlie Quinine Side Effects, University of Nottingham Study

Positive CHMP Opinion for s JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen

Broad Therapy For Muscular Dystrophy, Ohio State University Study

Irish Court Invalidates Patent on GlaxoSmithKline's Top Drug

Clavis Pharma ASA Raises $20 Million in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates

Pfizer Inc.'s Sutent Effective vs Rare Pancreatic Cancer

Japan Approves First Generic Biotech Drug Somatropin From Novartis AG

Reuters - Japanese regulators approved a human growth hormone from Novartis AG, the first green light in Japan for a biosimilar or generic version of a biotech drug, the Swiss drugmaker said on Thursday.

EU Body Backs TiGenix Cartilage Product, Shares Up

Bio And Medical Device Companies Come To Grips With Gift Ban

Documents Shed Light on s Stealth Venture, Evoke Pharma, Inc.

xconomy.com -- The mystery surrounding San Diegos Evoke Pharma is beginning to clear. The specialty drug company co-founded by serial entrepreneur Cam Garner has been operating in stealth mode and has said little about the experimental drug it is developing for gastroparesis, a digestive disorder that affects diabetics. But a recent quarterly filing from a third party, Questcor of Hayward, Calif...

MYMETICS Corporation's Board of Directors Announces the Appointment of as President and CEO

NYON, Switzerland, June 26, 2009 (GLOBE NEWSWIRE) -- Mymetics (www.mymetics.com) Corporation (OTCBB:MYMX), today announced that its Board of Directors has named Jacques-Francois Martin as Chairman of the Board, President and CEO, effective July 1, 2009, replacing Christian Rochet who remains as a non executive Director.

PPD, Inc.'s Creation of 300 Research Campus Jobs Evaporates

New Cancer Treatment Being Called A Medical Breakthrough, Study

Drug Firms' Medical Staffs Say What Salespeople Can't

WSJ -- Pharmaceutical companies are barred by the Food and Drug Administration from promoting unapproved drug uses, called off-label use, but they are using employees called "medical science liaisons," who are often physicians and pharmacists, as a legal way to discuss those uses.

UK Scientists Say They've Found A Cure For Crohn's, University of Nottingham Study

Guardian -- People suffering from the debilitating bowel condition Crohn's disease may be cured using a groundbreaking stem cell treatment, according to the British doctor leading the research.

EU Agency Backs New Centocor Ortho Biotech Inc., Schering-Plough Corporation Arthritis Drug

EMEA Recommends Withdrawal of Dextropropoxyphene-Containing Medicines

Doctor's Guide -- Finalising a review of the safety and efficacy of dextropropoxyphene-containing medicines, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) concluded that their risks, particularly the risk of potentially fatal overdose, are greater than their benefits.

Novo Growth Equity Expands Team, and Will Invest Up to $200M Per Year

Industry veterans Scott A. Beardsley and Michael Shalmi join the team as senior partners </p><p>COPENHAGEN & BAGSVAERD, Denmark--(BUSINESS WIRE)--Novo Growth Equity, an investment activity of Novo A/S, announced today that it has expanded its leadership team in Copenhagen. Industry veterans Scott Beardsley and Michael Shalmi have joined the team as senior partners. Christina Sylvester-Hvid also...

ISTA Pharmaceuticals, Inc. Wins US Panel Support for Eye Itch Drug

Insmed Incorporated Drug, Iplex Fails in Genetic Disorder Study, Shares Tank

FDA Approves First Generic Version of Emergency Contraceptive Plan B by Watson Laboratories, Inc.; Prescription Only for Women 17 and Younger

UCB Group Arthritis Drug Cimzia Wins EU Watchdog Approval

Deloitte Consulting Finds NJ Lost 1,400 Pharma and Med Device Jobs in 2008 Amid Rising Economic Impact

ULURU Inc. Discussions to Acquire York Pharma PLC Terminated

AEterna Zentaris Receives $10 Million from Institutional Investors

Consumer Advocacy Groups like Urge FDA To Release Info On Rejected Drugs And Devices

MediciNova, Inc. and Avigen, Inc. Confirm Understanding for Key Terms for a Business Combination

SAN DIEGO and ALAMEDA, Calif., June 25, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), and Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company, today announced that they have confirmed their understanding of certain key terms for...